Dicerna Pharmaceuticals Inc (DRNA)

3.07
0.03 0.97
NASDAQ : Health Care
Prev Close 3.10
Open 3.10
Day Low/High 3.02 / 3.11
52 Wk Low/High 2.69 / 15.93
Volume 19.48K
Avg Volume 106.00K
Exchange NASDAQ
Shares Outstanding 20.84M
Market Cap 67.95M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Market Limps Into Weekend

Market Limps Into Weekend

After ripping higher earlier in the week, stocks went into consolidation mode Friday.

Dicerna Expands Lead GalXC™ Development Program To Encompass All Forms Of Primary Hyperoxaluria (PH) And Reveals New Therapeutic Target For DCR-PHXC

Dicerna Expands Lead GalXC™ Development Program To Encompass All Forms Of Primary Hyperoxaluria (PH) And Reveals New Therapeutic Target For DCR-PHXC

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of ribonucleic acid interference (RNAi) therapeutics, presented on Saturday, July 15, 2017, new preclinical data suggesting the potential utility of DCR-PHXC,...

Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that based on recommendations from the Compensation Committee of...

Dicerna Announces Appointment Of Ralf Rosskamp, M.D., As Chief Medical Officer

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of industry veteran Ralf Rosskamp, M.

Dicerna To Present At Jefferies 2017 Global Healthcare Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna Reports First Quarter 2017 Financial And Operational Results And Provides Corporate Update

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operational results for the first quarter ended March 31,...

Dicerna To Report First Quarter 2017 Financial Results And Host Conference Call On May 8, 2017

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2017 financial results...

Dicerna Announces Closing Of $70 Million Convertible Preferred Stock Financing

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company"), a leading developer of investigational ribonucleic acid interference ("RNAi") therapeutics, today announced that it has closed its previously announced stock...

Dicerna Reports Fourth Quarter And Full Year 2016 Financial And Operational Results

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operational results for the fourth quarter and full year...

Dicerna Secures $70 Million In Convertible Preferred Stock Financing

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it has signed a stock purchase agreement with a...

Dicerna Pharmaceuticals To Present At The BioCentury 24th Annual Future Leaders In The Biotech Industry Conference

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna To Report Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call On March 30, 2017

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2016...

Dicerna To Present At Cowen And Company 37th Annual Health Care Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna To Participate In Fireside Chat At The Leerink Partners Global Healthcare Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 31, 2017, the Compensation Committee of the Company's Board of...

Dicerna To Present At The Stifel 2016 Healthcare Conference

Dicerna To Present At The Stifel 2016 Healthcare Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna Reports Third Quarter 2016 Financial And Operational Results

Dicerna Reports Third Quarter 2016 Financial And Operational Results

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the third quarter ended September 30, 2016.

Dicerna To Report Third Quarter 2016 Financial Results And Host Conference Call On November 7, 2016

Dicerna To Report Third Quarter 2016 Financial Results And Host Conference Call On November 7, 2016

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2016 financial results after market...

Dicerna Prioritizes Resources To Advance GalXC™ Product Candidates

Dicerna Prioritizes Resources To Advance GalXC™ Product Candidates

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will focus its resources on its proprietary GalXC TM...

Dicerna To Present At September Investor Conferences

Dicerna To Present At September Investor Conferences

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna Reports Second Quarter 2016 Financial And Operational Results

Dicerna Reports Second Quarter 2016 Financial And Operational Results

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the second quarter ended June 30, 2016.

Dicerna To Report Second Quarter 2016 Financial Results And Host Conference Call On August 4, 2016

Dicerna To Report Second Quarter 2016 Financial Results And Host Conference Call On August 4, 2016

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2016 financial results after market...

New Preclinical Data Show Potential Of Dicerna GalXC™ Subcutaneous Delivery Platform As RNAi Drug Discovery Engine

New Preclinical Data Show Potential Of Dicerna GalXC™ Subcutaneous Delivery Platform As RNAi Drug Discovery Engine

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today will unveil preclinical data showing the promise of its proprietary GalXC TM...

7 Stocks Under $10 Making Big Moves

7 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Dicerna Appoints Martin Freed, M.D., To Board Of Directors

Dicerna Appoints Martin Freed, M.D., To Board Of Directors

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of Martin Freed, M.

Dicerna To Present At The Jefferies 2016 Healthcare Conference

Dicerna To Present At The Jefferies 2016 Healthcare Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna Announces Dosing Of First Patient In Phase 1 Clinical Trial Of DCR-PH1 In Patients With Primary Hyperoxaluria Type 1 (PH1)

Dicerna Announces Dosing Of First Patient In Phase 1 Clinical Trial Of DCR-PH1 In Patients With Primary Hyperoxaluria Type 1 (PH1)

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has dosed the first patient in its DCR-PH1-101 trial, the first Phase 1...

Dicerna Reports Potent Preclinical Activity With GalNAc-DsiRNA-EX Conjugates

Dicerna Reports Potent Preclinical Activity With GalNAc-DsiRNA-EX Conjugates

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today will present updated preclinical data demonstrating the potency of its proprietary...